Breaking News

Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

Looks to secure a supply agreement for the only inactivated vaccine candidate in clinical trials against COVID-19 in EU.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Valneva SE is now focusing on discussions, on a country by country basis, to supply its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, and is consequently deprioritizing the ongoing centralized discussions with the European Commission (EC). This follows the recent announcement on April 6, 2021 of positive initial results from the Phase 1/2 clinical trial of VLA20011. Read more here.   Valneva previously announced the advanced stage of its discussions with the EC on January 12,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters